Rational Vaccine Design in the Time of COVID-19

Dennis R Burton; Laura M Walker

doi:10.1016/j.chom.2020.04.022

Rational Vaccine Design in the Time of COVID-19

Cell Host Microbe. 2020 May 13;27(5):695-698. doi: 10.1016/j.chom.2020.04.022.

Authors

Dennis R Burton¹, Laura M Walker²

Affiliations

¹ The Scripps Research Institute, La Jolla, CA 92037, USA; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA. Electronic address: burton@scripps.edu.
² Adimab, Lebanon, NH 03766, USA. Electronic address: laura.walker@adimab.com.

Abstract

As scientists consider SARS-CoV-2 vaccine design, we discuss problems that may be encountered and how to tackle them by what we term "rational vaccine design." We further discuss approaches to pan-coronavirus vaccines. We draw on experiences from recent research on several viruses including HIV and influenza, as well as coronaviruses.

MeSH terms

AIDS Vaccines / immunology
AIDS Vaccines / standards
Antibodies, Viral / immunology*
Antigens, Viral / immunology*
Betacoronavirus / immunology*
COVID-19
COVID-19 Vaccines
Coronavirus Infections / immunology
Coronavirus Infections / prevention & control*
Humans
Influenza Vaccines / immunology
Influenza Vaccines / standards
Pandemics / prevention & control*
Pneumonia, Viral / immunology
Pneumonia, Viral / prevention & control*
Research Design / trends
SARS-CoV-2
Viral Vaccines / immunology*

Substances

AIDS Vaccines
Antibodies, Viral
Antigens, Viral
COVID-19 Vaccines
Influenza Vaccines
Viral Vaccines